First Transfemoral Implantation of a Novel Transcatheter Valve in an LVAD Patient With Aortic Insufficiency
Key result
Transfemoral implantation of the JenaValve Trilogy transcatheter heart valve successfully treated severe aortic regurgitation in an LVAD patient, resolving hemolysis and improving symptoms at 6 months.
Population
An 80-year-old man with a destination LVAD and decompensated heart failure
Comparison
Aortic valve replacement with a novel transcatheter valve and LVAD pump exchange
Design
Case report
Authors
Discussion
Loading...
Member takes
Implication
Offers a potential option for AR in LVAD patients; leaves open durability, safety, and generalizability pending larger studies.
Study Design
Type
Case Report (n=1)
Multicenter
No
Structured PICO
P
Population
An 80-year-old man with a destination LVAD presenting with decompensated heart failure, severe aortic regurgitation, and hemolysis, followed for 6 months.
I
Intervention
Aortic valve replacement with a novel transcatheter valve and LVAD pump exchange.
O
Outcome
Improvement in clinical status
Transfemoral implantation of a novel transcatheter aortic valve combined with LVAD pump exchange is feasible and can improve clinical status in patients with LVAD-associated severe aortic regurgitation.
Limitations
- Single case report
- Short-term follow-up of 6 months
Cite This Study
Ranard et al. (2021) conducted a case report in Aortic insufficiency in a patient with a left ventricular assist device (LVAD) (n=1). JenaValve Trilogy transcatheter heart valve system was evaluated on Clinical status and resolution of hemolysis and aortic regurgitation. Transfemoral implantation of the JenaValve Trilogy transcatheter heart valve successfully treated severe aortic regurgitation in an LVAD patient, resolving hemolysis and improving symptoms at 6 months.